EyePoint Pharmaceuticals, Inc. (EYPT) Stock

EyePoint Pharmaceuticals, Inc. (EYPT) is a Technology stock trading at $5.41 (as of 2026-08-20), with a market capitalization of $466.41M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

EyePoint Pharmaceuticals, Inc. develops and commercializes ophthalmic therapies for eye diseases. Its products include ILUVIEN, YUTIQ, and DEXYCU, and it is also developing EYP-1901 and YUTIQ50; the company operates in the United States, China, and the United Kingdom.

Understand EyePoint Pharmaceuticals, Inc.: how it makes money

EyePoint Pharmaceuticals develops and commercializes ophthalmic drugs, including injectable sustained-release and intravitreal implant therapies and an intraocular suspension, and it makes money primarily through net product sales, with additional potential revenue from licenses and royalties.

Profit is driven by net product revenue from its ophthalmic treatments (sustained-release and implant-based therapies), with any licenses and royalties acting as a secondary revenue stream.

Revenue by segment (latest quarter)
Utique$0.0B
UTEAQQ$0.0B
Dexa-Q$0.0B
Lic/Royalties$0.0B

Business quality (Weak): Facts provided support a clear product-driven revenue engine, but the latest reported revenue is extremely small in the dataset, so trend and impact are hard to judge from this snapshot alone.

Bull case

  • Demand visibility for key products: The company discloses customer demand for Dexa-Q units and Utique units, which can help indicate market uptake for these therapies.
  • Clinical development progress is being tracked with enrollment milestones: The company reports Phase 3 enrollment completed (wet age-related macular degeneration), and it also tracks other study enrollment and patient treatment metrics.

Bear case

  • Revenue appears concentrated in a limited set of product lines: Segment candidates show net product revenue categories for specific ophthalmic products, while licenses and royalties are shown as 0.0B in this dataset.
  • Clinical execution risk can affect timelines: The company reports a dropout rate and detailed enrollment metrics, which implies that trial progression can be sensitive to patient retention and study operations.
Valuation — source: SEC EDGAR (first-party)
Price$5.41
Market Cap$466.41M
Price / Book2.80
Price / Sales167.29
FCF Yield-94.3%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$31.37M
Net Margin-739.4%
Revenue Growth (YoY)-90.5%
EPS Growth (YoY)28.2%
FCF Growth (YoY)-0.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.73 (distress)
Valuation vs Sector & Industry
Sector P/E (Technology)33.9
Industry P/E (Measuring & Control Equipment)51.8
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderSUVRETTA CAPITAL MANAGEMENT, LLC ($106.94M)
Institutional Holders Tracked10
Company
SectorTechnology
IndustryMeasuring & Control Equipment
CEOJay S. Duker
Employees165
CountryUS
IPO Date2005-01-27

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Avantor, Inc. (AVTR)
  • Bruker Corporation (BRKR)
  • 10x Genomics, Inc. (TXG)
  • BIO-RAD LABORATORIES, INC. (BIO)
  • Alamar Biosciences, Inc. (ALMR)
  • Cytek Biosciences, Inc. (CTKB)
  • Pacific Biosciences of California, Inc. (PACB)
  • Harvard Bioscience, Inc. (HBIO)
EYPT earnings history · EYPT institutional & insider holders · EYPT KPIs & operating metrics · EYPT financials · EYPT investor presentations & press releases · EYPT SEC filings · EYPT peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.